Total
0
Shares
Clinuvel (ASX:CUV) - CEO, Dr Philippe Wolgen
CEO, Dr Philippe Wolgen
Source: The Market Herald
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Clinuvel Therapeutics has renewed its employment agreement with Managing Director Dr Philippe Wolgen for three years
  • Dr Philippe has steered the company since its restructure in 2005
  • He was instrumental in the $95 million capital raise for the funding of SCENESSE
  • Clinuvel has ended the day up 4.15 per cent, trading for $27.10 per share

Clinuvel Therapeutics has renewed the employment agreement with life science executive and Managing Director Dr Philippe Wolgen for three years.

According to the Board of Directors, Dr Philippe has steered the company since its restructure in 2005 to its current successful position.

“The Board of Directors and larger investors are clear in their opinion that we want to retain Philippe and see him supported by a stable senior management team in order to continue the Company’s successful journey,” Chair, Stan McLiesh said.

“We believed that successful execution of our strategy should see continued growth in shareholder value. I am grateful to all who have contributed to finalise this positive outcome for the Company today,” Stan added.

Dr Philippe holds an MBA from Columbia University NY and the London Business School.

He is trained as a craniofacial surgeon and holds an MD from the University of Utrecht in the Netherlands.

He has held positions in private pharmaceutical companies in Europe, been Managing Director of two medical centres in the U.K. and Israel, and consulted medical device companies.

Dr Philippe has been instrumental in raising $95 million since 2006 for the funding of the current development program of SCENESSE.

Its SCENESSE product is designed to assist people who have erythropoietic protoporphyria: a condition which leaves skin hypersensitive to the sun causing pain or burning.

In light of this news Clinuvel has ended the day up 4.15 per cent with shares priced at $27.10 apiece.

CUV by the numbers
More From The Market Herald

" Crown Resorts (ASX:CWN) keeps Vic. licence despite damning report

Crowns Resorts (CWN) will keep its Victorian casino licence despite a damning report labelling the operator’s behaviour as “illegal, dishonest, unethical and exploitative”.

" Smartgroup Corporation’s (ASX:SIQ) takeover offer abandoned

An offer to buy out all of the shares in Smartgroup Corporation (SIQ) and take over the employee management services business has been
Aussie Broadband (ASX:ABB) - Managing Director, Phillip Britt

" Aussie Broadband (ASX:ABB) confirms takeover talks with Over The Wire (ASX:OTW)

In response to an article by The Australian, Aussie Broadband (ABB) has confirmed it is in discussions with Over The Wire (OTW) regarding
Cashrewards (ASX:CRW) - CEO, Bernard Wilson

" ANZ’s (ASZ:ANZ) investment arm to buy Cashrewards (ASX:CRW)

ANZ’s (ANZ) investment arm will aim to buy all of the share in fellow ASX-lister Cashrewards (CRW).